Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
remdesivir
Biotech
Gilead nixes oral COVID-19 antiviral to focus on internal asset
Gilead has pulled out of an oral COVID-19 antiviral project, focusing on its own approach at the expense of its collaborator’s LNC platform.
Nick Paul Taylor
Jan 31, 2023 6:40am
NRx hopes 'guided missile' COVID-19 antiviral will get FDA nod
Jun 2, 2021 9:45am
Plasma therapy backed by CSL, Takeda fails phase 3 COVID-19 test
Apr 5, 2021 7:55am
Gilead's virology lead Brainard jumps ship to AlloVir
Mar 23, 2021 7:25am
Could this low-cost leprosy drug be repurposed for COVID-19？
Mar 17, 2021 10:15am
Cancer drug outperforms remdesivir in COVID-19 models
Jan 27, 2021 8:40am
